TSG6 is involved in the therapeutic effects of MSCs in treating IBD, such as mucosal barrier recovery through activating endogenous stem cells [96–99], and immune modulation [49, 50, 97, 100–102]. This evidence concerns the gene TNFAIP6 and inflammatory bowel disease.